With the aim to enhance the effect of WIP1 inhibitors, we performed a drug combination screening where we combined the WIP1 inhibitor SL-176 with 527 different clinical and experimental cancer compounds from different drug classes in two different neuroblastoma cell lines. The gene discussed is PPM1D; the disease is cancer.